**Name of Author:- Rutuja Nagmoti 1st , Hemant Narule 2nd , Nikhil Chaudhari 3rd ,**

 **Bhavana Patil 4th , Gayatri Mahale 5th , Prajwal Mahajan 6th ,**

 **Jaydeep Wanare 7th , Pragati Kuwar 8th**

**Title:- Treatment of various fungal infections that appeared in Skin, Nails & Hair.**

**ABSTRACT**

Fungal infections on the skin are now widely treated. In part, this has been accomplished through the creation and assessment of brand-new medications. Utilizing novel approaches, such as finding differences in responsiveness between various species, as in tinea capitis, as well as looking for more effective means of guaranteeing enough medication concentrations in the skin or nail, and combining these approaches, The various therapy approaches have all been crucial in ensuring that the outcomes of the treatment have steadily improved. A greater rate of remission and cure for fungal nail disease, as well as the creation of efficient community treatments, are two areas where we currently seek improvement. initiatives to combat the widespread scalp ringworm.

**Keywords:** Dermatophytes; cutaneous candidiasis; Malassezia infection; treatment; onychomycosis

**1.Introduction**

All across the world, a fungus commonly infects the skin as well as its adnexal structures like hair and nails. Nevertheless, over the past 40 years, there have been significant advancements in the management of these conditions, from the time when the majority of the treatments were straightforward antiseptics with some antifungal activity to the present when there is a wide and expanding range of specific antifungal antimicrobials. With the possible exception of superficial Candida infections, where azole resistance is well known, modern treatment has not been without its challenges, but the problems frequently associated with antibacterials, particularly drug resistance, have not significantly affected the currently used antifungals.

Due to this and selection pressure, species with lesser azole sensitivity have become more prevalent, including Candida glabrata. Even while to date it has not significantly affected skin infection, superficial carriage of the pathogen Candida Auris, which is commonly multidrug-resistant, is well established and is a cause for concern. Drug toxicity is not a significant issue, but it does create a unique risk management conundrum when it does occur, albeit infrequently, in the context of the care of non-life-threatening illnesses. The revocation of oral ketoconazole's recognition by regulatory authorities in Europe and the US for the treatment of surface infections serves as an example of how the risk-benefit ratio differs from that experienced with systemic mycoses.



**Fig 1. Fungal infections of the Skin, Hair, and Nails**

****

**Fig 2. Fungal infections of the skin**

**2.1 Dermatophytosis**

With cure rates between 80 and 90% for the majority of skin-related dermatophyte infections, medical treatment has produced excellent outcomes. As a result, a variety of antifungal drugs are currently being used as topical or oral formulations [1–4]. Providing they are used consistently and for the suggested lengths of time, all of these are successful in the majority of patients. In the most recent study Complete cure—including complete clinical cure [5]—is the primary aim for clinical trials evaluating antifungal efficacy for dermatophytosis, with mycological recovery serving as a supplementary endpoint. This is not completely gratifying because the changes that are clinically visible may take longer to improve than expected. in illnesses like tinea pedis, which are responsible for the organisms' self-destruction.

Typically, topical therapies are used for "localized" infections or those with limited dissemination, and oral treatments are used for more widespread infections for treating dermatophytosis that affects the skin. Due to the fact that many patients find it time-consuming and challenging to apply topical medications repeatedly, compliance is frequently a significant problem [6]. Due to this, several antifungals have been evaluated in trials after a single or small number of applications, as opposed to the more common twice-daily therapy applications.

**2.1.1 Treatments applied topically**

Skin infections caused by dermatophytes have been treated with a wide range of topical treatments [1,2,7–10]. With this strategy, severe side effects are quite unlikely, and allergic or irritating contact dermatitis is also extremely infrequent.

Clotrimazole, miconazole, econazole, and ketoconazole are examples of imidazole preparations for topical use that have a solid track record of treating ringworm infections with little to no side effects [1-3]. Other medications in this class, such as tioconazole [11] and sulconazole [12], also work well for treating ringworm infections. Sertaconazole [13], luliconazole [13], and isoconazole [14] are novel preparations that have joined these earlier topicals, however, they have not yet received worldwide approval. Typically, cream, solution, or spray formulations of the azole antifungals come in 1% concentration. However, some, like bifonazole, are only allowed to be used once daily [15]. The majority are taken twice daily for 2-4 weeks. The effectiveness of the various azoles is essentially the same [16].

The topical application of 1% terbinafine is an efficient substitute therapy [17, 18]. In some dermatophyte infections, such as interdigital tinea pedis, terbinafine cream used locally in dermatophytosis causes remissions after only brief durations of administration, such as seven days. For infections of the foot and sole, terbinafine is also available as a topical film-forming solution that is applied once [19]. After applying the solution, it needs to dry for 3–4 minutes. Butenafine [21] and naftifine [20] are two additional useful allylamines. For usage in treating dermatophytosis, ciclopirox is offered as a topical treatment in several nations [4].

Tolnaftate and zinc undecenoate, as well as other older cream or powder formulations, are available over the counter.

**2.1.2 Oral antifungal medications**

Dermatophyte skin infections respond well to oral antifungals (Table 1). For dermatophytosis, 250 mg of terbinafine is used orally daily. After two weeks, dry-type tinea pedis, tinea cruris, and tinea corporis all experience quick and persistent remissions [22]. In some nations, children can be treated with 125 mg tablets, which are smaller. Itraconazole is efficacious in regimens of 100 mg for 2 weeks in tinea corporis and cruris, or 30 days in dry-type tinea pedis [23]. It is also effective against a wide variety of dermatophytes. For tinea corporis for one week and dry-type tinea pedis for two weeks, the currently recommended regimen is 400 mg/day [24, 25]. Periods of treatment need longer on occasion. Itraconazole has been reformulated and is now accessible in some countries [26] with improved absorption. Dermatophyte infections of the skin are treated with fluconazole at a dose of 50 mg daily for 2-4 weeks [27]. For tinea corporis and tinea cruris, it can also be taken in a 150 mg/week regimen for 2–3 weeks, but for dry-type tinea pedis, it should be used for longer [28,29].

Adults who need an alternative medication should take ketoconazole 200–400 mg/day. Ketoconazole is no longer prescribed for surface infections in Europe and the United States because of the known risk of hepatitis, which occurs at a rate of about 2.9 events/1000 person-years [30]. Apart from rare occurrences of profound dermatophytosis, there is currently limited information on the use of posaconazole [31] and voriconazole [32] for tinea infections. Although more recent oral medications such as pramiconazole for tinea corporis [33], ravuconazole for onychomycosis [34], and albaconazole for dermatophyte infections [35] have undergone in vitro testing or phase 1 to 2 clinical studies, they are not currently available for these uses. With a dose of 10 mg/kg/day administered as a tablet, griseofulvin is primarily used to treat dermatophyte infections [25]. Despite being unavailable in many nations, there is a solution form for kids. For tinea corporis or cruris, the course of treatment can take 2 to 4 weeks.

Table 1 Treatment of dermatophyte infections systemically (summary).

|  |  |  |
| --- | --- | --- |
|  | First line | Alternative |
| Toenail fungus (dry type) | Terbinafine 250 mg every day for two weeks200–400 mg of itraconazole each day for a week | 6 mg/kg/week for 4-6 weeks of fluconazole |
| The corpus tinea (extensive) | 250 mg of terbinafine per day for a week200 mg every day of itraconazole for a week | 150–200 mg fluconazole every week for two to four weeks |
| Dermatophytes are the cause of onychomycosis | 12 weeks of terbinafine 250 mg per day (toenails)and six weeks (fingernails)200 mg dose of itraconazole every week or month for(Toenails) 3 months or 2 months (fingernails) | Fluconazole 150-200 mg/week for 3–4 months or 6–9 months (toenails) (fingernails) |
| The Tinea capitis (children) | Terbinafine 125 mg (25 kg), 187.5 mg (25-35 kg), or 250 mg (>35 kg) once a day for three to four weeksmostly infections caused by Trichophyton 10-15 mg/kg/day of griseofulvin for six to eight weeks primary infections from Microsporum | 4–8 weeks, 5 mg/kg/day of itraconazole (up to 500 mg) |

\*A combination of oral and topical antifungals, such as amorolfine or ciclopirox, is helpful in severe infections, especially those affecting the nail matrix. Although there have been few clinical trials, this could need to be paired with surgical removal, such as after 40% urea or laser ablation.

There are some tinea infections, typically caused by T. rubrum, that initially respond to therapy with either terbinafine or itraconazole but recur soon [36]. These infections typically affect the groin or the trunk. A variety of treatment plans, including combinations of oral azole or allylamine medicines and topical azole or allylamines, have been attempted anecdotally. There isn't a consistently efficient solution for these problems as of now. Similar issues have been brought up in India, where large lesions are frequently present together with persistent tinea corporis or cruris [37], which is often the result of T. interdigital. Contrarily, tinea infections of the skin in immunocompromised individuals, particularly those with HIV/AIDS, typically respond to treatment, albeit it is frequently necessary to twice the recommended dosage [38].

**2.2 Skin infection caused by Candida**

A variety of antifungals available in cream, powder, or solution formulations work effectively to treat skin-related Candida infections [39, 40]. Azole medications are effective antifungals for candidosis (econazole, clotrimazole, ketoconazole, and miconazole). The topical versions of polyene antifungal medications such as nystatin, amphotericin B, and natamycin are additional antifungal medicines that are not appropriate for treating dermatophytosis [41]. The majority of the time, these therapies work well for treating superficial Candida infections of the skin and mucous membranes. Nevertheless, the majority of clinical studies have concentrated on vaginal or oropharyngeal infections or cutaneous involvement in chronic mucocutaneous candidiasis (CMC).

Fluconazole and itraconazole are the two oral medications used the most frequently to treat candidosis, with most research concentrating on mucosal infection or CMC. Itraconazole and fluconazole are often taken in doses of 100 to 200 mg each day. It is well-known that there is a problem with fluconazole resistance. a long-term course of medication has been recorded in individuals with HIV/AIDS or CMC. There may be resistant and sensitive strains of Candia identified in oral infection, demonstrating the variability of the population in infection [44]; it is unclear if this also holds true for cutaneous infections. Patients with long-term infections that require suppressive therapy and immunosuppressed individuals are prone to developing drug resistance. These infections are typically oral or intravaginal in nature rather than cutaneous, and they frequently require suppressive therapy. resistance to the primary drug Several species of Candida have been linked to fluconazole, as well as C. krusei, C. dubliniensis, C. glabrata, and C. Auris. Patients with candidosis who are taking highly active antiretroviral (HAART) medication had a lower incidence of Candida resistance. Voriconazole and posaconazole are two more azoles that work against Candida species [45, 46]. These two have both been used to treat severe oropharyngeal and oesophageal infections in the critically unwell, but not Candida skin infections.

Candida in the flexures. This is a reference to the condition known as Candida intertrigo, which affects flexures like the groins or inframammary fold. Azole or polyene creams must be used topically for two weeks [1, 2], while treatment may be prolonged for longer lengths of time. In many situations where the damp skin surface can cause significant discomfort, drying the diseased location is also vital.

**2.3 Malassezia Infections**

Pityriasis Verna. The cure rate for pityriasis Versicolor can reach over 85% when a variety of antifungal medications are used [47]. Miconazole, clotrimazole, ketoconazole, and sertaconazole are azole antifungals that can be used topically and are effective in treating pityriasis Versicolor. Different antifungal substances provide the same results [48], with azole creams being the most popular form of application. Ciclopirox is also useful in treating pityriasis Versicolor, as are allylamines that can be administered topically, such as terbinafine 1% cream, naftifine, or butenafine [49]. Recovery typically takes two to three weeks across all treatments. The large surface area involved in this condition's treatment is one of the practical difficulties.

Using a drug that can be distributed more evenly throughout the body, like a mousse-like keto mousse, is one way to get around this [50]. Although the effectiveness of ketoconazole shampoo in treating pityriasis Versicolor has not been fully studied, most infections seem to be cleared after two to three applications spread out over a week. Applying 2.5% selenium sulfide to a detergent base (Selsun® shampoo) is a different strategy [51]. After applying it everywhere that is impacted, it is left on for the night. Frequently, the item must be used on a regular basis, such as every other night for two weeks.

Even while itraconazole is typically used for severe or recalcitrant instances of pityriasis Versicolor, it is also quite effective when taken orally [52]. In a total dosage of 800-1000 mg, often spread out over 5 days, itraconazole is effective against pityriasis Versicolor. A substitute is a fluconazole [53].

The oral medication works well for treating Malassezia folliculitis. For instance, itraconazole is used orally once daily for two to three weeks [54]. Because it's important to guarantee that the topical antifungal medication gets to the hair follicles, this infection responds to it less consistently than other fungal infections.

A few investigations on the effectiveness of azole antifungals in seborrheic dermatitis have been conducted. The most successful ketoconazole-containing drugs were those that were topically administered to the scalp or facial skin, according to a systematic review [55] on the topic. Studies in a similar vein with the effective medications bifonazole and selenium sulfide. Other azoles have been shown to be useful in clinical settings, and in severe situations, oral itraconazole 100 mg daily can be used to bring on remission for 10–14 days. Patients should be made aware of the fact that this ailment frequently and on a regular basis relapse, which is a practical concern regardless of the treatment chosen.

**2.4 Tinea Capitis**

Except as an adjuvant to oral medication to control the spread or treat carriers, topical antifungal medicines are rarely used in the management of tinea capitis [56]. Utilizing oral antifungals (Table 1), such as terbinafine, itraconazole, griseofulvin, or fluconazole, is the mainstay of treatment for tinea capitis, which primarily affects youngsters [57–60]. Other oral antifungals, particularly the more recent azoles like voriconazole or posaconazole, are not supported by clinical research. However, in general, standard daily medication is advised (10–15 mg/kg), and treatment durations of at least 6 weeks are typically sufficient. Single-dose therapy with griseofulvin and intermittent dosing regimens (25 mg/kg twice a week) have shown some success. It is utilized mainly in situations brought on by Microsporum species.

Some infections, including those brought on by T. tonsurans, may require griseofulvin therapy for considerably longer durations and occasionally at higher doses (20 mg/kg/day) [56]. Not many nations have a sufficient liquid version of griseofulvin on hand.

Terbinafine is the preferred treatment option for some infections, such as those brought on by Trichophyton species, despite the fact that not all countries have approved it for use in children [58,59]. However, there are less data and the medication seems to work less well for conditions brought on by Microsporum species. With terbinafine, one month seems to be the ideal amount of time for treating T. tonsurans and T. violaceum infections. There is some evidence to support the idea that greater terbinafine doses (twice the recommended amount) may be more successful in treating Microsporum. Both itraconazole and fluconazole appear to be effective against T. tonsurans, but the ideal duration of treatment has not yet been determined.

The following are recommended dosages for treating tinea capitis in children:

Terbinafine—under 10 kg, between 10 and 20 kg, and over 20 kg—all daily for four weeks.

2-4 mg/kg/day of itraconazole for 4-6 weeks

10 mg/kg/six to eight weeks of griseofulvin (20 mg/kg/some T. tonsurans infections)

Terbinafine was recommended for scalp Trichophyton infections, according to a comprehensive review that also used extra published data, while griseofulvin was preferred for Microsporum infections [59].

In addition to oral medication, patients in the early stages of therapy may use ketoconazole shampoo or selenium sulfide two to three times a week to avoid transmission. Siblings of patients with anthropophilic tinea capitis are treated in a manner similar to this. If a culture of scalp scrapings or brushings is positive but the scalp is clinically normal, the person is believed to be a carrier who has viable fungi on their scalp without invading the hair shaft [57, 60, 61]. Many doctors advise treating this condition with antifungal shampoos, as explained above.

**2.5 Onychomycosis**

A number of new advancements in the treatment of fungal nail infections have been made in an effort to increase the success rates of healing. These advancements include increasing the ability of antifungals to penetrate the nail plate or combining antifungal therapy with the surgical excision or laser ablation of the infected nail plate. Other novel techniques include the use of photodynamic therapy and iontophoresis. Similar to other superficial mycoses, the target endpoint for the majority of recent clinical trials is a complete cure. Clinically normal nails treated with mycological treatment are what is meant by this. Previous research employed various endpoints, such as incorporating treatments for nails with little or no remaining clinical change. Comparisons between various studies have become challenging as a result. Variations in research and follow-up lengths have caused another issue with interpretation. Numerous more recent combination techniques There aren't many clinical trials with sufficient follow-up times that have been well-documented for treatment.

**2.5.1 Onychomycosis Topical Treatments for Dermatophytes**

The creation of numerous innovative antifungal medication formulations with improved nail penetration has recently made topical therapy for onychomycosis conceivable. With no need for laboratory monitoring, topical treatment is thought to be safer. However, when given over a lengthy period of time, such as several months, or protracted regimens, compliance with a regular topical regimen is frequently poor. The use of topicals is typically limited to situations when the nail matrix is unaffected and the nail plate has not thickened significantly.

antibiotics that are azoles. Onychomycosis has been treated well using the older topical azole antifungals, such as clotrimazole and miconazole, in 1% cream or solution formulations. success. However, some unique azoles have also been created to especially address nail therapy. Tioconazole and bifonazole are two of these azoles that have been applied topically in the management of onychomycosis, and they were the first to be launched. A 28% solution of tioconazole is how it's made. In 22% of cases with finger- and toe-nail onychomycosis, it has been discovered to achieve a clinical cure 3 months following therapy [62].

Another topical imidazole, bifonazole, has been utilized in urea paste formulations at a 40% concentration. Patients then apply bifonazole cream on a regular basis while the nail grows out after first applying urea-containing bifonazole to the nail plate when it is occluded [63]. Using novel azole drugs has been a feature of the most recent topical treatments. The nail plate and skin around it are treated with fluconazole, a triazole antifungal that is administered once daily. Efinaconazole has shown reduced keratin affinity, enhancing nail penetration, and exists as a 10% solution in various nations. The rate of complete recovery ranges from 15 to 18% [64, 65]. A similar efficacy rate of new azole is miconazole, a broad-spectrum imidazole in a 5% solution. A favorable safety and tolerability profile was shown for the solution formulation [66]. In some nations, onychomycosis can be treated with these medications.

Transungual delivery systems are available for atomolfine. The solvent evaporating from the film after the application of the 5% lacquer increases the amorolfine concentration to 27% at the nail surface in just 3-5 minutes. In patients undergoing once-weekly or twice-weekly treatment, respectively, a complete cure was recorded in 46% and 52% of cases. But it's crucial to remember that in this study, a complete cure was deemed to exist when the mycology was negative and the nail involvement was under 10% [67]. Comparing this to more recent research employing novel medicines and stricter criteria is challenging.

A hydroxypyridone derivative called ciclopirox inhibits metal-dependent enzymes, which interferes with the transport of nutrients and amino acids. It works by chelating trivalent cations like Al3+ and Fe3+. It can be purchased as an 8% lacquer to treat onychomycosis. Complete cure rates of 5.5-8.5% were obtained in two investigations applying strict criteria [68,69]. Another brand-new antifungal drug that is available as a 5% solution is avaborole. It belongs to a brand-new class of antifungals that contain boron and work by inhibiting the formation of cytoplasmic leucyl-transfer ribonucleic acid (tRNA) synthetase in fungi. Complete cure rates of 6.5% and 9.1% were noted in two vehicle-controlled, double-blind investigations that used 5% tavaborole solution once daily for 48 weeks [70].

The development of more topical antifungals, including those using terbinafine as the active ingredient, for use in nail diseases is ongoing. However, with more time and experience, there may be more information available on long-term relapse rates with the new topicals.

**Oral antifungals**

In comparison to topical treatments, oral antifungal medications have had higher success rates (Table 1). To treat dermatophyte onychomycosis and other dermatophyte infections, terbinafine is one of the most often prescribed antifungals. For toenail onychomycosis, a daily dose of 250 mg was required for 12 weeks, while for fingernails, it was required for 6 weeks. The total and mycological cure rates were reported to be 38% and 70% in numerous investigations with slightly different assessment criteria [71–73]. Comparative studies are also included. For instance, oral terbinafine displayed greater efficacy compared to the more established drugs itraconazole when administered at 250 mg daily for 12–16 weeks. and griseofulvin [54], as well as fluconazole. Terbinafine resulted in a complete cure rate of 35% (vs. 14%) in a trial contrasting continuous terbinafine therapy with intermittent itraconazole therapy [74]. Exercise caution. be administered to people who have liver disease. However, current findings indicate that this is not always essential. Many doctors routinely check liver enzymes.

For toenail onychomycosis, it is prescribed at a dose of 400 mg daily for one week every three to four months, and for fingernail infections, at a dose of 200 mg daily for six weeks [75]. Itraconazole is also given intermittently at a dose of 400 mg daily for one week every month for three to four months [75]. Mycological cure rates for itraconazole averaged 59% for continuous therapy and 63% for pulsed therapy in a meta-analysis of randomized controlled trials [76]. Average rates of clinical and mycological toenail cures were found in another meta-analysis of trials comparing continuous and pulsed treatments. Itraconazole was continually dosed at 200 mg per day for three months, with onychomycosis rates at 12 months following the commencement of treatment of 86% and 74%, respectively. At a 12-month follow-up, the average clinical and mycological cure rates for toenail onychomycosis treated with three pulses of itraconazole at 400 mg daily for one week each month were 82% and 77%, respectively. For fingernail onychomycosis, the cure rates were greater [77].

Itraconazole can have gastrointestinal and neurological adverse effects, such as headaches and vertigo, as well as, less frequently, hepatotoxicity and morbilliform or pustular skin rashes. Congestive cardiac failure is a significant but extremely uncommon adverse effect. Similar to oral terbinafine, certain patients may need laboratory monitoring.

Onychomycosis has also demonstrated efficacy for fluconazole [78]. The typical fluconazole dosage for For fingernails it takes 150 mg once a week for six months, and for toenails, it takes 12 months [79]. The percentage of patients with clinical cures (totally healthy-appearing nails) at the end of treatment ranged from 28 to 36%.

The most successful dosing regimen for posaconazole is to administer 200 mg daily as an oral suspension for 24 weeks to achieve a full cure (54.1%). As a result, posaconazole may offer an alternative for individuals with non dermatophyte infections or those who cannot tolerate terbinafine [80], but it is currently pricey.

**Onychomycosis Alternative Therapies**

When treating onychomycosis, medical (non-pharmaceutical) devices and methods are becoming more and more crucial, whether they are used alone or in conjunction with other topical or oral antifungal medications. Lasers, iontophoresis, and UV radiation are some of the methods that have been examined recently; however, there aren't any long-term follow-up studies or randomized controlled trials that assess the effectiveness of individual devices or combinations of therapies at this time [81–83].

On the idea of selective photothermolysis, laser therapy is founded. In order to achieve this, specific chromophores must be targeted in order to cause localized damage with little harm to the healthy tissue nearby. Laser therapy for onychomycosis has been the subject of numerous investigations. Analysis There are relatively minor side effects from using lasers, according to 22 research. Drawing reliable findings, however, is challenging due to the diversity in study designs. There have been variations in treatment plans and goals, and these studies often only included small patient groups. The cure requirements, as previously mentioned, have varying definitions. Although there is typically good initial improvement in appearance, there is currently no solid evidence that laser therapy is useful for onychomycosis over the long term [84,85].

The most popular lasers for onychomycosis treatment are Nd: YAG laser systems. Ablative lasers like carbon dioxide and erbium have been employed as well as diode lasers, which operate at temperatures safe for human tissues [67]. using laser and Treatment with a particular antifungal medication, such as topical amorolfine, may also work well [86,87], but more research is required.

Following topical application of photosensitizing substances including 5-aminolevulinic acid (ALA), methyl aminolevulinate, and methylene blue (MB) and exposure to a light source, photodynamic treatment (PDT) uses a phototoxic reaction that takes place. Numerous skin malignancies are treated with it on a regular basis. Again, a lack of rigorously controlled trials with sufficient follow-up information hinders the evaluation of its usage in onychomycosis, despite the fact that it is promising [88-90].

Iontophoresis, a different physical technique, has been used for medications like terbinafine gel formulation. It involves transporting pharmacologically active molecules into the nail by using a low-voltage electric field. Simple mechanical debridement, chemical (40% urea), and surgical nail plate avulsion are three categories of surgical procedures [91–94]. Again, they can be coupled with antifungals that are either orally or used locally. The application of various antifungals, such as butenafine or terbinafine, into the holes made in the nail plate surface and subsequent diffusion of the active compounds into the nail tissue, are other techniques that have been used to form small wells in the nail plate [95].

**2.5.2. Other Organisms Can Cause Onychomycosis**

Treatment options for Candida-related nail dystrophy include oral itraconazole, fluconazole, or ketoconazole as well as chemical removal followed by local antifungal therapy [96]. Combination avulsion and antifungal medication should be utilized if these approaches fail. The recommended dose of itraconazole may need to be increased to 200 mg per day in cases with persistent mucocutaneous candidosis. Treatment should end once remission is achieved. Rarely has resistance to this medication been noted. Bacterial invasion of the nail fold and Candida infection are common complications of Candida paronychia. contact dermatitis or secondary irritant. In this case, topical corticosteroids are frequently used in conjunction with oral or topical antifungals. Due to the enlarged nail fold's continued potential as an entrance point for both irritants and germs, the problem usually recurs. An operation to remove the fibrotic tissue observed in chronic nail fold swelling can help with this [97].

Other nail fungal infections, such as those brought on by Fusarium, Neoscytalidium, or Scopulariopsis, are typically treated by anecdotal experience because there aren't enough cases to warrant conducting a research trial. In these situations, a variety of therapeutic modalities are frequently employed, such as oral and topical medications like amorolfine, antifungals, and nail plate ablation.

**3. Summary**

The majority of fungal diseases of the skin have undergone significant advancements in their treatment, including the development of new antifungal medications, formulations, and auxiliary physical methods. go to treatment. Impressive outcomes were obtained. Work needs to be done in a few places still. It still takes a long time to treat many nail-related fungal infections, and the treatments are sometimes unreliable or even ineffective. Onychomycosis therapies must be more efficient and brief, and they must be supported by strong clinical trial results. Moreover, the method of treatment is flawed. various superficial fungi diseases in low-resource environments, such as tinea capitis, In kids of school age, prevalence rates might go above 25%. in these circumstances, affordable would lead to effective control if it were supported by a public health strategy. Despite medication resistance, The ongoing epidemic of superficial fungal infections is not perceived as a major issue, although dermatophyte infections that are difficult to cure and have previously been reported in India are of worry [37]. Sporadic imported cases, even though there is little proof to suggest a risk of immediate spread In other nations, cases are becoming more widely known. understanding the causes of Priority is given to infections that respond normally to therapy.

**References**

1. Gupta, A.K.; Sauder, D.N.; Shear, N.H. Antifungal agents: An overview. Part I. J. Am. Acad. Dermatol. 1994, 30, 677–698. [CrossRef]

2. Gupta, A.K.; Sauder, D.N.; Shear, N.H. Antifungal agents: An overview. Part II. J. Am. Acad. Dermatol. 1994, 30, 911–933. [CrossRef]

3. Crawford, F.; Hollis, S. Topical treatments for fungal infections of the skin and nails of the foot. Cochrane Database Syst. Rev. 2007, 3, CD001434. [CrossRef] [PubMed]

4. Rotta, I.; Ziegelmann, P.K.; Otaki, M.F.; Riveros, B.S.; Bernardo, N.L.; Correr, C.J. Efficacy of topical antifungals in the treatment of dermatophytosis: A mixed-treatment comparison meta-analysis involving 14 treatments. JAMA Dermatol. 2013, 149, 341–349. [CrossRef] [PubMed]

5. Gupta, A.K.; Einarson, T.R.; Summerbell, R.C.; Shear, N.H. An overview of topical antifungal therapy in dermatomycoses. A North American perspective. Drugs 1998, 55, 645–674.[CrossRef][PubMed]

6. Weinberg, J.M. Increasing Patient Adherence in Antifungal Infection Treatment. J. Clin. Aesthet.Dermatol.2009,2,38-42.[PubMed]

7. Ramam, M.; Prasad, H.R.; Manchanda, Y.; Khaitan, B.K.; Banerjee, U.; Mukhopadhyaya, A.; Gogtay, J.A. Randomised controlled trial of topical butenafine in tinea cruris and tinea corporis Indian J. Dermatol. Venereol. Leprol. 2003, 69, 154–158.

8. Gupta, A.K.; Bluhm, R. Ciclopirox (Loprox) gel for superficial fungal infections. Skin Ther. Lett. 2004, 9, 4–5.

9. Bakos, L.; Brito, A.C.; Castro, L.C.; Gontijo, B.; Lowy, G.; Reis, C.M.S.; Zaitz, C. Open clinical study of the efficacy and safety of terbinafine cream 1% in children with tinea corporis and tinea cruris. Pediatr. Infect. Dis. J. 1997, 16, 545–548. [CrossRef] [PubMed]

10. Borelli, C.; Klövekorn, G.; Ernst, T.M.; ödeker, R.H.; Korting, H.C.; Neumeister, C. Comparative study of 2% sertaconazole solution and cream formulations in patients with tinea corporis, tinea pedis interdigital, or a corresponding candidosis. Am. J. Clin. Dermatol. 2007, 8,371-378.[CrossRef][PubMed]

11. Fredriksson, T. Treatment of Dermatomycoses with Topical Tioconazole and Miconazole. Dermatology 1983, 166, 14–19. [CrossRef]

12. Benfield, P.; Clissold, S.P. Sulconazole A Review of its Antimicrobial Activity and Therapeutic Use in Superficial Dermatomycoses. Drugs 1988, 35, 143–153. [CrossRef] [PubMed]

13. Jerajani, H.; Janaki, C.; Kumar, S.; Phiske, M. Comparative assessment of the efficacy and safety of sertaconazole (2%) cream versus terbinafine cream (1%) versus luliconazole (1%) cream in patients with dermatophytoses: A pilot study. Indian J. Dermatol. 2013, 58, 34–38. [CrossRef] [PubMed]

14. Veraldi, S.; Persico, M.C.; Schianchi, R. Isoconazole nitrate vs isoconazole nitrate and diflucortolone valerate in the treatment of tinea inguinalis: Results of a multicenter retrospective study. J. Drugs Dermatol. 2012, 11, E70–E73. [PubMed]

15. Rotta, I.; Sanchez, A.; Gonçalves, P.R.; Otuki, M.F.; Correr, C.J. Efficacy and safety of topical antifungals in the treatment of dermatomycosis: A systematic review. Br. J. Dermatol. 2012, 166, 927–933. [CrossRef] [PubMed]

16. El-Gohary, M.; van Zuuren, E.J.; Fedorowicz, Z.; Burgess, H.; Doney, L.; Stuart, B.; Little, P. Topical antifungal treatments for tinea cruris and tinea corporis. Cochrane Database Syst. Rev. 2014, 8, CD009992. [CrossRef] [PubMed]

17. Evans, E.G. Tinea pedis: Clinical experience and efficacy of short treatment. Dermatology 1997, 194, 3–6. [CrossRef] [PubMed]

18. Budimulja, U.; Bramono, K.; Urip, K.S.; Basuki, S.; Widodo, G.; Rapatz, G.; Paul, C. Once daily treatment with terbinafine 1% cream (Lamisil) for one week is effective in the treatment of tinea corporis and cruris. A placebo-controlled study. Mycoses 2001, 44, 300–306. [CrossRef] [PubMed]

19. Ortonne, J.P.; Korting, H.C.; Viguié-Vallanet, C.; Larnier, C.; Savaluny, E. Efficacy and safety of a new single-dose terbinafine 1% formulation in patients with tinea pedis (athlete’s foot): A randomized, double-blind, placebo-controlled study. J. Eur. Acad. Dermatol. Venereol. 2006, 20, 1307–1313. [CrossRef] [PubMed]

20. Plaum, S.; Verma, A.; Fleischer, A.B., Jr.; Hardas, B. Detection and relevance of naftifine hydrochloride in the stratum corneum up to four weeks following the last application of naftifine cream and gel, 2%. J. Drugs Dermatol. 2013, 12, 1004–1008. [PubMed]

21. Tanuma, H.; Doi, M.; Ohta, Y.; Abe, M.; Kume, H.; Mukai, H.; Katsuoka, K. Butenafine hydrochloride (Mentax) cream for the treatment of hyperkeratotic type tinea pedis and its transfer into the horny layer, with or without concomitant application of 20% urea ointment (Keratinamin). Mycoses 2001, 44, 287–299. [CrossRef] [PubMed]

22. Keyser, P.D.; Backer, M.D.; Massart, D.L.; Westelinck, K.J. Two-week oral treatment of tinea pedis, comparing terbinafine (250 mg/day) with itraconazole (100 mg/day): A double-blind, multicentre study. Br. J. Dermatol. 1994, 130, 22–25. [CrossRef] [PubMed]

23. Saul, A.; Bonifaz, A. Itraconazole in common dermatophyte infections of the skin: Fixed treatment schedules. J. Am. Acad. Dermatol. 1990, 23, 554–558. [CrossRef]

24. Bell-Syer, S.E.; Khan, S.M.; Torgerson, D.J. Oral treatments for fungal infections of the skin of the foot. Cochrane Database Syst. Rev. 2012, 10, CD003584. [CrossRef] [PubMed]

25. Degreef, H.J.; DeDoncker, P.R. Current therapy of dermatophytosis. J. Am. Acad. Dermatol. 1994, 31, S25–S30. [CrossRef]

26. Clinicaltrials.gov. Bioavailability Study of Lozanoc™ 65 mg Itraconazole Capsules in Patients Requiring Prophylaxis 2016. Available online: https://clinicaltrials.gov/ct2/show/NCT02755857 (accessed on 1 June 2018).

27. Nozickova, M.; Koudelkova, V.; Kulikova, Z.; Malina, L.; Urbanowski, S.; Silny, W. A comparison of the efficacy of oral fluconazole, 150 mg/week versus 50 mg/day, in the treatment of tinea corporis, tinea cruris, tinea pedis, and cutaneous candidosis. Int. J. Dermatol. 1998, 37, 703–705. [CrossRef] [PubMed]

28. Stary, A.; Sarnow, E. Fluconazole in the treatment of tinea corporis and tinea cruris. Dermatology 1998, 196, 237–241. [CrossRef] [PubMed]

29. Montero-Gei, F.; Perera, A. Therapy with Fluconazole for Tinea Corporis, Tinea Cruris, and Tinea Pedis. Clin. Infect. Dis. 1992, 14, S77–S80. [CrossRef] [PubMed]

30. Re, V.L.; Carbonari, D.M.; Lewis, J.D.; Forde, K.A.; Goldberg, D.S.; Reddy, K.R.; Schneider, J.L. Oral Azole Antifungal Medications and Risk of Acute Liver Injury, Overall and by Chronic Liver Disease Status. Am. J. Med. 2016, 129, 283–291. [PubMed]

31. Jachiet, M.; Lanternier, F.; Rybojad, M.; Bagot, M.; Ibrahim, L.; Casanova, J.L.; Bouaziz, J.D. Posaconazole Treatment of Extensive Skin and Nail Dermatophytosis Due to Autosomal Recessive Deficiency of CARD9. JAMA Dermatol. 2015, 151, 192–194. [CrossRef] [PubMed]

32. Cheng, C.Y.; Hsiao, Y.H.; Ko, J.H. Disseminated deep dermatophytosis caused by Trichophyton rubrum in deep dermatophytosis affecting the skin. Dermatol. Sin. 2014, 32, 191–192. [CrossRef]

33. Decroix, J.; Ausma, J.; Cauwenbergh, G.; Borgers, M.; Wouters, L. The efficacy of oral treatment with pramiconazole in tinea pedis and tinea cruris/corporis: Two exploratory phase IIa trials. Br. J. Dermatol. 2008, 158, 854–856. [CrossRef] [PubMed]

34. Gupta, A.K.; Leonardi, C.; Stoltz, R.R.; Pierce, P.F.; Conetta, B. A phase I/II randomized, double-blind, placebo-controlled, dose-ranging study evaluating the efficacy, safety and pharmacokinetics of ravuconazole in the treatment of onychomycosis. J. Eur. Acad. Dermatol. Venereol. 2005, 19, 437–443. [CrossRef] [PubMed]

35. Welshenbaugh, A.R.; Angulo, D.; Ghannoum, M. Time kill activity of albaconazole against agents of onychomycosis and tinea capitis. In Proceedings of the Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, USA, 17–20 September 2007; Volume 47.

36. Moriarty, B.; Hay, R.; Morris-Jones, R. The diagnosis and management of tinea. BMJ 2012, 345, E4380. [CrossRef] [PubMed]

37. Sahoo, A.K.; Mahajan, R. Management of tinea corporis, tinea cruris, and tinea pedis: A comprehensive review. Indian Dermatol. Online J. 2016, 7, 77–86. [PubMed]
38. WHO Guidelines on the Treatment of Skin and Oral HIV-Associated Conditions in Children and Adults World Health Organization. 2014. Available online: <http://www.who.int/maternal_child_adolescent/> documents/skin-mucosal-and-hiv/en/ (accessed on 1 June 2018).

39. Edwards, J.E. Candida species. In Principles and Practice of Infectious Diseases, 8th ed.; Mandell, G.L., Bennett, J.E., Dolin, R., Eds.; Churchill Livingstone: Philadelphia, PA, USA, 2015; pp. 2879–2894.

40. Subissi, A.; Monti, D.; Togni, G.; Mailland, F. Ciclopirox: Recent nonclinical and clinical data relevant to its use as a topical antimycotic agent. Drugs 2010, 70, 2133–2135. [CrossRef] [PubMed]

41. Ellepola, A.N.; Samaranayake, L.P. Oral candidal infections and antimycotics. Crit. Rev. Oral Biol. Med. 2000, 11, 172–198. [CrossRef] [PubMed]

42. Grant, S.M.; Clissold, S.P. Fluconazole: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses. Drugs 1990, 39, 877–916. [CrossRef] [PubMed]

43. Grant, S.M.; Clissold, S.P. Itraconazole: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in superficial and systemic mycoses. Drugs 1989, 37, 310–344. [CrossRef] [PubMed]

44. Sun, J.; Qi, C.; Lafleur, M.D.; Qi, Q.G. Fluconazole susceptibility and genotypic heterogeneity of oral Candida albicans colonies from the patients with cancer receiving chemotherapy in China. Int. J. Oral Sci. 2009, 1, 156–161. [CrossRef] [PubMed]

45. Ianas, V.; Matthias, K.R.; Klotz, S.A. Role of posaconazole in the treatment of oropharyngeal candidiasis. Infect. Drug Resist. 2010, 3, 45–51. [PubMed]

46. Gligorov, J.; Bastit, L.; Gervais, H.; Henni, M.; Kahila, W.; Lepille, D. Candidoscope Study Group. Prevalence and treatment management of oropharyngeal candidiasis in cancer patients: Results of the French CANDIDOSCOPE study. Int. J. Radiat. Oncol. Biol. Phys. 2011, 80, 532–539. [CrossRef] [PubMed]

47. Hu, S.W.; Bigby, M. Pityriasis versicolor: A systematic review of interventions. Arch Dermatol. 2010, 146, 1132–1140. [CrossRef] [PubMed]

48. Gupta, A.K.; Foley, K.A. Antifungal Treatment for Pityriasis Versicolor. J. Fungi 2015, 1, 13–29. [CrossRef]
[PubMed]

49. Gold, M.H.; Bridges, T.; Avakian, E.; Plaum, S.; Pappert, E.J.; Fleischer, J.A.; Hardas, B. An open-label study of naftifine hydrochloride 1% gel in the treatment of tinea versicolor. Skinmed 2011, 9, 283–286. [PubMed]

50. Di Fonzo, E.M.; Martini, P.; Mazzatenta, C.; Lotti, L.; Alvino, S. Comparative efficacy and tolerability of Ketomousse (ketoconazole foam 1%) and ketoconazole cream 2% in the treatment of pityriasis versicolor: Results of a prospective, multicentre, randomised study. Mycoses 2008, 51, 532–535. [CrossRef] [PubMed]

51. Hull, C.A.; Johnson, S.M. A double-blind comparative study of sodium sulfacetamide lotion 10% versus selenium sulfide lotion 2.5% in the treatment of pityriasis (tinea) versicolor. Cutis 2004, 73, 425–429. [PubMed]

52. Crespo Erchiga, V.; Delgado Florencio, V. Malassezia species in skin diseases. Curr. Opin. Infect. Dis. 2002, 15, 133–142. [CrossRef] [PubMed]

53. Farschian, M.; Yaghoobi, R.; Samadi, K. Fluconazole versus ketoconazole in the treatment of tinea versicolor. J. Dermatol. Treat. 2002, 13, 73–76. [CrossRef] [PubMed]

54. Parsad, D.; Saini, R.; Negi, K.S. Short-term treatment of Pityrosporum folliculitis: A double-blind placebo-controlled study. J. Eur. Acad. Dermatol. Venereol. 1998, 11, 188–190. [CrossRef] [PubMed]

55. Naldi, L. Seborrhoeic dermatitis. Clin. Evid. 2010, 2010, 1713.

56. Elewski, B.E. Tinea capitis: A current perspective. J. Am. Acad. Dermatol. 2000, 42, 1–20. [CrossRef]

57. Fuller, C.F.; Barton, R.C.; Mohd Mustapa, M.F. British Association of Dermatologists’ Guidelines for the Management of Tinea Capitis. 2014. Available online: <http://www.bad.org.uk/shared/get-file.ashx?id=> 2022&itemtype=document (accessed on 1 June 2018).

58. González, U.; Seaton, T.; Bergus, G.; Jacobson, J.; Martínez-Monzón, C. Systemic antifungal therapy for tinea capitis in children. Cochrane Database Syst. Rev. 2007, 4, CD004685.

59. Tey, H.L.; Tan, A.S.; Chan, Y.C. Meta-analysis of randomized, controlled trials comparing griseofulvin and terbinafine in the treatment of tinea capitis. J. Am. Acad. Dermatol. 2011, 64, 663–670. [CrossRef] [PubMed]

60. Babel, D.; Baughman, S.A. Evaluation of the carrier state in juvenile tinea capitis caused by Trichophyton tonsurans. J. Am. Acad. Dermatol. 1989, 21, 1209–1212. [CrossRef]

61. Alvarez, M.S.; Silverberg, N.B. Tinea capitis. Cutis 2006, 78, 189–196. [PubMed]

62. Hay, R.J.; Mackie, R.M.; Clayton, Y.M. Tioconazole nail solution—An open study of its efficacy in onychomycosis. Clin. Exp. Dermatol. 1985, 10, 111–115. [CrossRef] [PubMed]

63. Friedman-Birnbaum, R.; Cohen, A.; Shemer, A.; Bitterman, O.; Bergman, R.; Stettendorf, S. Treatment of onychomycosis: A randomized, double-blind comparison study with topical bifonazole-urea ointment alone and in combination with short-duration oral griseofulvin. Int. J. Dermatol. 1997, 36, 67–69. [CrossRef] [PubMed]
64. Elewski, B.; Rich, P.; Pollak, R.; Pariser, D.M.; Watanabe, S.; Senda, H.; Olin, J.T. Efinaconazole 10% solution in the treatment of toenail onychomycosis: Two phase III multicenter, randomized, double-blind studies. J. Am. Acad. Dermatol. 2013, 68, 600–608. [CrossRef] [PubMed]

65. Vlahovic, T.C.; Joseph, W.S. Efinaconazole topical, 10% for the treatment of toenail onychomycosis in patients with diabetes. J. Drugs Dermatol. 2014, 13, 1186–1190. [PubMed]

66. Jones, T.; Tavakkol, A. Safety and Tolerability of Luliconazole Solution 10-Percent in Patients with Moderate to Severe Distal Subungual Onychomycosis. Antimicrob. Agents Chemother. 2013, 57, 2684–2689. [CrossRef] [PubMed]

67. Zaug, M.; Bergstraesser, M. Amorolfine in the treatment of onychomycoses and dermatomycoses (an overview). Clin. Exp. Dermatol. 1992, 17, 61–70. [CrossRef] [PubMed]

68. Gupta, A.K.; Fleckman, P.; Baran, R. Ciclopirox nail lacquer topical solution 8% in the treatment of toenail onychomycosis. J. Am. Acad. Dermatol. 2000, 43, S70–S80. [CrossRef] [PubMed]

69. Gupta, A.K.; Joseph, W.S. Ciclopirox 8% nail lacquer in the treatment of onychomycosis of the toenails in the United States. J. Am. Podiatr. Med. Assoc. 2000, 90, 495–501. [CrossRef] [PubMed]

70. Elewski, B.E.; Aly, R.; Baldwin, S.L.; Soto, R.F.G.; Rich, P.; Weisfeld, M.; Pollak, R. Efficacy and safety of tavaborole topical solution, 5%, a novel boron-based antifungal agent, for the treatment of toenail onychomycosis: Results from 2 randomized phase-III studies. J. Am. Acad. Dermatol. 2015, 73, 62–69. [CrossRef] [PubMed]

71. Darkes, M.J.M.; Scott, L.J.; Goa, K.L. Terbinafine: A review of its use in onychomycosis in adults. Am. J. Clin. Dermatol. 2003, 4, 39–65. [CrossRef] [PubMed]

72. Sigurgeirsson, B.; Billstein, S.; Rantanen, T. LION. Study: Efficacy and tolerability of continuous terbinafine (Lamisil) compared to intermittent itraconazole in the treatment of toenail onychomycosis. Lamisil vs. Itraconazole in Onychomycosis. Br. J. Dermatol. 1999, 141, 5–14. [CrossRef] [PubMed]

73. De Sá, D.C.; Lamas, A.P.B.; Tosti, A. Oral therapy for onychomycosis: An evidence-based review. Am. J. Clin. Dermatol. 2014, 15, 17–36. [CrossRef] [PubMed]

74. Tosti, A.; Piraccini, B.M.; Stinchi, C.; Venturo, N.; Bardazzi, F.; Colombo, M.D. Treatment of dermatophyte nail infections: An open randomized study comparing intermittent terbinafine therapy with continuous terbinafine treatment and intermittent itraconazole therapy. J. Am. Acad. Dermatol. 1996, 34, 595–600. [CrossRef]

75. Maddin, S.; Quiring, J.; Bulger, L. Randomized, placebo-controlled, phase 3 study of itraconazole for the treatment of onychomycosis. J. Drugs Dermatol. 2013, 12, 758–763. [PubMed]

76. Gupta, A.K.; Ryder, J.E.; Johnson, A.M. Cumulative meta-analysis of systemic antifungal agents for the treatment of onychomycosis. Br. J. Dermatol. 2004, 150, 537–544. [CrossRef] [PubMed]

77. Gupta, A.K.; De Doncker, P.; Scher, R.K.; Haneke, M.D.E.; Daniel, R.C.; André, J.; Baran, R. Itraconazole for the treatment of onychomycosis. Int. J. Dermatol. 1998, 37, 303–308. [CrossRef] [PubMed]

78. Elewski, B.E. Onychomycosis: Pathogenesis, diagnosis and management. Clin. Microbiol. Rev. 1998, 11, 415–429. [CrossRef] [PubMed]

79. Scher, R.K.; Breneman, D.; Rich, P.; Savin, R.C.; Feingold, D.S.; Konnikov, N.; Aly, R. Once-weekly fluconazole (150, 300, 450 mg) in the treatment of distal subungual onychomycosis of the toenail. J. Am. Acad. Dermatol. 1998, 38, S77–S86. [CrossRef]

80. Elewski, B.; Pollak, R.; Ashton, S.; Rich, P.; Schlessinger, J.; Tavakkol, A. A randomized, placebo- and active-controlled, parallel-group, multicentre, investigator-blinded study of four treatment regimens of posaconazole in adults with toenail onychomycosis. Br. J. Dermatol. 2012, 166, 389–398. [CrossRef] [PubMed]

81. Nematollahi, A.R.; Badiee, P.; Nournia, E. The Efficacy of Ultraviolet Irradiation on Trichophyton Species Isolated From Nails. Jundishapur J. Microbiol. 2015, 8, E18158. [CrossRef] [PubMed]

82. Nair, A.B.; Vaka, S.R.K.; Murthy, S.N. Transungual delivery of terbinafine by iontophoresis in onychomycotic nails. Drug Dev. Ind. Pharm. 2011, 37, 1253–1258. [CrossRef] [PubMed]

83. Abadi, D.; Zderic, V. Ultrasound-mediated nail drug delivery system. J. Ultrasound Med. 2011, 30, 1723–1730. [CrossRef] [PubMed]

84. Nenoff, P.; Grunewald, S.; Paasch, U. Laser therapy of onychomycosis. J. Dtsch Dermatol. Ges. 2014, 12, 33–38. [CrossRef] [PubMed]

85. Bhatta, A.K.; Huang, X.; Keyal, U.; Zhao, J.J. Laser treatment for onychomycosis: A review. Mycoses 2014, 57, 734–740. [CrossRef] [PubMed]

86. Karsai, S.; Jager, M.; Oesterhelt, A.; Weiss, C.; Schneider, S.W.; Jünger, M.; Raulin, C. Treating onychomycosis with the short-pulsed 1064-nm-Nd YAG laser: Results of a prospective randomized controlled trial. J. Eur. Acad. Dermatol. Venereol. 2017, 31, 175–180. [CrossRef] [PubMed]

87. De Morais, O.O.; Costa, I.M.C.; Gomes, C.M.; Shinzato, D.H.; Ayres, G.M.C.; Cardoso, R.M. The use of the ER YAG 2940 nm laser associated with amorolfine lacquer in the treatment of onychomycosis. An. Bras. Dermatol. 2013, 88, 847–849.

88. Zhang, J.; Lu, S.; Huang, H.; Li, X.; Cai, W.; Ma, J.; Xi, L. Combination therapy for onychomycosis using a fractional 2940-nm Er:YAG laser and 5% amorolfine lacquer. Lasers Med Sci. 2016, 31, 1391–1396. [CrossRef] [PubMed]

89. Gilaberte, Y.; Robres, M.P.; Frias, M.P.; García-Doval, I.; Rezusta, A.; Aspiroz, C. Methyl aminolevulinate photodynamic therapy for onychomycosis: A multicenter, randomized, controlled clinical trial. J. Eur. Acad. Dermatol. Venereol. 2017, 31, 347–354. [CrossRef] [PubMed]

90. Souza, L.W.F.; Souza, S.V.T.; Botelho, A.C.C. Distal and lateral toenail onychomycosis caused by Trichophyton rubrum: Treatment with photodynamic therapy based on methylene blue dye. An. Bras Dermatol. 2014, 89, 184–186. [CrossRef] [PubMed]

91. Cohen, P.R.; Scher, R.K. Topical and surgical treatment of onychomycosis. J. Am. Acad. Dermatol. 1994, 31, S74–S77. [CrossRef]

92. Di Chiacchio, N.; Kadunc, B.V.; de Almeida, A.R.T.; Madeira, C.L. Nail abrasion. J. Cosmet. Dermatol. 2003, 2, 150–152. [CrossRef] [PubMed]

93. Malay, D.S.; Yi, S.; Borowsky, P.; Downey, M.S.; Mlodzienski, A.J. Efficacy of debridement alone versus debridement combined with topical antifungal nail lacquer for the treatment of pedal onychomycosis: A randomized, controlled trial. J. Foot Ankle Surg. 2009, 48, 294–308. [CrossRef] [PubMed]

94. Jennings, M.B.; Pollak, R.; Harkless, L.B.; Kianifard, F.; Tavakkol, A. Treatment of toenail onychomycosis with oral terbinafine plus aggressive debridement: IRON-CLAD, a large, randomized, open-label, multicenter trial. J. Am. Podiatr. Med. Assoc. 2006, 96, 465–473. [CrossRef] [PubMed]

95. Shemer, A.; Gupta, A.K.; Amichai, B.; Farhi, R.; Baran, R.; Daniel, C.R.; Foley, K.A. An open comparative study of nail drilling as adjunctive treatment for toenail onychomycosis. J. Dermatol. Treat. 2016, 27, 480–483. [CrossRef] [PubMed]

 96. Baran, R.; Hay, R.J.; Garduno, J.I. Review of antifungal therapy, part II: Treatment rationale, including specific patient populations. J. Dermatol. Treat. 2008, 19, 168–175. [CrossRef] [PubMed]

97. D’almeida, L.F.V.; Papaiordanou, F.; Machado, E.A.; Loda, G.; Baran, R.; Nakamura, R. Chronic paronychia treatment: Square flap technique. J. Am. Acad. Dermatol. 2016, 75, 398–403.

.